Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies
PLoS MedicinePublished 27 September 2011Open access
Patricia McGettigan, David Henry
Citations561
SJR quartileQ1
SJR score4.28
SNIP3.21
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
David Henry and colleagues reevaluate the evidence from observational studies on the cardiovascular risk associated with non-steroidal anti-inflammatory drugs and suggest that these studies should be considered as outliers.
Abstract
This review suggests that among widely used NSAIDs, naproxen and low-dose ibuprofen are least likely to increase cardiovascular risk. Diclofenac in doses available without prescription elevates risk. The data for etoricoxib were sparse, but in pair-wise comparisons this drug had a significantly higher RR than naproxen or ibuprofen. Indomethacin is an older, rather toxic drug, and the evidence on cardiovascular risk casts doubt on its continued clinical use. Please see later in the article for the Editors' Summary.
Keywords
Medicine
Medical Entomology and ZoologyThe Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
17,869 Citations2014George A. Wells
The goal of this project is to develop an instrument providing an easy and convenient tool for quality assessment of nonrandomised studies to be used in a systematic review.
New England Journal of MedicineComparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
4,017 Citations2000Claire Bombardier, Loren Laine +10 more
In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
BMJInteraction revisited: the difference between two estimates
3,135 Citations2003Douglas G. Altman, J Martin Bland
BMJDo selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
1,431 Citations2006Patricia M. Kearney, Colin Baigent +4 more
Selective COX 2 inhibitors are associated with a moderate increase in the risk of vascular events, as are high dose regimens of ibuprofen and diclofenac, but high dose naproxen is not associated with such an excess.
New England Journal of MedicineCyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
1,392 Citations2001Francesca Catella-Lawson, Muredach P. Reilly +6 more
The concomitant administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibition induced by aspirin, which may limit the cardioprotective effects of aspirin.
BMJCardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
1,164 Citations2011Sven Trelle, Stephan Reichenbach +6 more
Although uncertainty remains, little evidence exists to suggest that any of the investigated drugs are safe in cardiovascular terms, and Naproxen seemed least harmful.
JAMACardiovascular Risk and Inhibition of Cyclooxygenase
1,098 Citations2006Patricia McGettigan, David Henry
It is suggested that celecoxib in commonly used doses may not increase the risk, contradicts claims of a protective effect of naproxen, and raises serious questions about the safety of diclofenac, an older drug.
New England Journal of MedicineComplications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
1,094 Citations2005Nancy A. Nussmeier, Andrew Whelton +6 more
The use of parecoxib and valdecoxib after CABG was associated with an increased incidence of cardiovascular events, arousing serious concern about the use of these drugs in such circumstances.
New England Journal of MedicineCelecoxib for the Prevention of Sporadic Colorectal Adenomas
1,041 Citations2006Monica M. Bertagnolli, Craig Eagle +26 more
It is indicated that celecoxib is an effective agent for the prevention of colorectal adenomas but, because of potential cardiovascular events, cannot be routinely recommended for this indication.
Journal of Clinical InvestigationBiological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
1,007 Citations2005Tilo Großer
Questions that remain to be addressed are whether this hazard extends to all or some of the traditional NSAIDs; whether adjuvant therapies, such as low-dose aspirin, will mitigate the hazard and if so, at what cost; whether COX-2 inhibitors result in cardiovascular risk transformation during chronic dosing; and how to identify individuals most likely to benefit or suffer from such drugs in the future.
BMJVariability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis
827 Citations1996David Henry, L. Lim +10 more
The low risk of serious gastrointestinal complications with ibuprofen seems to be attributable mainly to the low doses of the drug used in clinical practice, and in higher doses ib uprofen is associated with a similar risk to other non-steroidal anti-inflammatory drugs.
Pharmacoepidemiology and Drug SafetySensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics
725 Citations2006Sebastian Schneeweiß
Large health care utilization databases are frequently used to analyze unintended effects of prescription drugs and biologics, causing residual confounding bias.
Journal of Pharmacology and Experimental TherapeuticsEffects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics, and Vasoactive Eicosanoids
595 Citations1999Francesca Catella-Lawson, Brendan McAdam +8 more
The data suggest that acute sodium retention by nonsteroidal anti-inflammatory drugs in healthy elderly subjects is mediated by the inhibition of Cox-2, whereas depression of GFR is due to inhibition ofcox-1.
The LancetCardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
519 Citations2006Christopher P. Cannon, Sean Curtis +10 more
Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs.
CirculationRelationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
506 Citations2004Daniel H. Solomon, Sebastian Schneeweiß +5 more
Current rofecoxib use was associated with an elevated relative risk of AMI compared with celecoxib use and no NSAID use, and Dosages of rofECoxib >25 mg were associated with a higher risk than dosages ≤25 mg, which was elevated in the first 90 days of use but not thereafter.
CirculationCardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials
358 Citations2008Scott D. Solomon, Janet Wittes +16 more
Evidence of differential cardiovascular risk as a function of celecoxib dose regimen and baseline cardiovascular risk is observed and may help guide treatment decisions for patients who derive clinical benefit from selective cyclooxygenase-2 inhibition.
CirculationDuration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction
330 Citations2011Anne‐Marie Schjerning Olsen, Emil Loldrup Fosbøl +10 more
Even short-term treatment with most NSAIDs was associated with increased risk of death and recurrent MI in patients with prior MI, and any NSAID use should be limited from a cardiovascular safety point of view.
PLoS MedicineMeta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview
271 Citations2011Su Golder, Yoon K. Loke +1 more
An overview of meta-analyses to assess whether estimates of the risk of harm outcomes differ between randomized trials and observational studies finds that, on average, there is no difference in the estimates of risk.
Lara D. VeekenGastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment [published erratum appears in Br J Rheumatol 1998 Oct;37(10):1142]
262 Citations1998C J Hawkey, André Kahan +9 more
The MELISSA trial confirms earlier studies suggesting that meloxicam has a significantly improved GI tolerability profile in comparison with other NSAIDs, including diclofenac, and provides support for the hypothesis that selective inhibition of COX-2 relative toCOX-1 might be an effective approach towards improved NSAID therapy.
Journal of the Royal Society of MedicineRisk of cardiovascular events and celecoxib: a systematic review and meta-analysis
226 Citations2006Brent Caldwell
The available data indicate an increased risk of myocardial infarction with celecoxib therapy, consistent with a class effect for COX-2 specific inhibitors.
CirculationNonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population
219 Citations2004Luis A. Garcı́a Rodrı́guez, Cristina Varas‐Lorenzo +2 more
The results do not support the existence of a clinically meaningful interaction between aspirin and NSAIDs, including ibuprofen, including aspirin taken concomitantly.
European Heart JournalNSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland
209 Citations2006Arja Helin‐Salmivaara
Current use of all NSAIDs is associated with a modest risk of first time MI, and all durations from 1 to 180 days of conventional NSAIDs and from 31 to 90 days duration of COX-2 selective NSAIDs were associated with an elevated risk of MI.
Basic & Clinical Pharmacology & ToxicologyNon‐Steroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction
202 Citations2006Sonia Hernández–Dı́az, Cristina Varas‐Lorenzo +1 more
Data suggest a small reduced risk for naproxen present only in non-users of aspirin, mainly people free of clinically apparent vascular disease.
Arthritis & RheumatismEfficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial
185 Citations2004Bernard R. Rubin, Robert Burton +10 more
Etoricoxib was comparable in efficacy to indomethacin at a dosage of 50 mg 3 times daily, and it was generally safe and well tolerated.
Circulation Cardiovascular Quality and OutcomesCause-Specific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals
166 Citations2010Emil Loldrup Fosbøl, Fredrik Folke +10 more
Individual NSAIDs have different degrees of cardiovascular safety, which must be considered when choosing appropriate treatment, and the results suggest that naproxen has a safer cardiovascular risk-profile.
New England Journal of MedicineRofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer
134 Citations2007David J. Kerr, Janet Dunn +9 more
Rofecoxib therapy was associated with an increased frequency of adverse cardiovascular events among patients with a median study treatment of 7.4 months' duration, and died from cardiovascular causes during the follow-up period.
GutChannelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs
110 Citations2003Thomas M. MacDonald, S V Morant +3 more
After attempting to correct for channelling bias, coxib exposure, but not meloxicam exposure, was associated with a significantly lower risk of gastrointestinal haemorrhage than older non-specific NSAIDs exposure.
Canadian Medical Association JournalTime variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors
68 Citations2006Linda E. Lévesque
A small proportion of patients using rofecoxib for the first time had their first MI shortly after starting the drug, and more research is needed to identify those most susceptible to cardiotoxicity mediated by COX-2 inhibitor therapy.
PLoS ONENSAID Use Selectively Increases the Risk of Non-Fatal Myocardial Infarction: A Systematic Review of Randomised Trials and Observational Studies
58 Citations2011Luis A. Garcı́a Rodrı́guez, Antonio González‐Pérez +2 more
The association between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of myocardial infarction (MI) is studied, separating non-fatal from fatal events, and summarizing the evidence from both observational studies and randomised controlled trials.
BMJFurther experience with indomethacin in the treatment of rheumatic disorders.
44 Citations1966M. Thompson, John Percy
As indomethacin became available for use in general practice in March 1965 the authors are recording the experience of a group of 137 patients treated with 25-mg.
Medicinal ChemistryInteractions Between Oxicams and Membrane Bilayers: an Explanation for Their Different COX Selectivity
41 Citations2006Marlene Lúcio, Helena Ferreira +2 more
Investigating the interactions between oxicams and biomembrane models proved that, in spite of structural similarities, oxicam present different interactions with membranes making possible a virtual division of the class in two groups.
Pharmacoepidemiology and Drug SafetyWhat happened to the prescribing of other COX‐2 inhibitors, paracetamol and non‐steroidal anti‐inflammatory drugs when rofecoxib was withdrawn in Australia?
31 Citations2007Nadia Barozzi, Susan E. Tett
How the prescribing of cyclooxygenase‐2 (COX‐2) inhibitors, non‐selective non‐steroidal anti‐inflammatory drugs (ns‐NSAIDs) and paracetamol (acetaminophen) changed when rofecoxib was withdrawn in 2004 is analyzed.